Canonical and Noncanonical Functions of the BH3 Domain Protein Bid in Apoptosis, Oncogenesis, Cancer Therapeutics, and Aging

Yetunde Makinwa,Yibo Luo,Phillip R. Musich,Yue Zou

DOI: https://doi.org/10.3390/cancers16122199

2024-06-13

Cancers

Abstract:Effective cancer therapy with limited adverse effects is a major challenge in the medical field. This is especially complicated by the development of acquired chemoresistance. Understanding the mechanisms that underlie these processes remains a major effort in cancer research. In this review, we focus on the dual role that Bid protein plays in apoptotic cell death via the mitochondrial pathway, in oncogenesis and in cancer therapeutics. The BH3 domain in Bid and the anti-apoptotic mitochondrial proteins (Bcl-2, Bcl-XL, mitochondrial ATR) it associates with at the outer mitochondrial membrane provides us with a viable target in cancer therapy. We will discuss the roles of Bid, mitochondrial ATR, and other anti-apoptotic proteins in intrinsic apoptosis, exploring how their interaction sustains cellular viability despite the initiation of upstream death signals. The unexpected upregulation of this Bid protein in cancer cells can also be instrumental in explaining the mechanisms behind acquired chemoresistance. The stable protein associations at the mitochondria between tBid and anti-apoptotic mitochondrial ATR play a crucial role in maintaining the viability of cancer cells, suggesting a novel mechanism to induce cancer cell apoptosis by freeing tBid from the ATR associations at mitochondria.

oncology

What problem does this paper attempt to address?

### What problem does this paper attempt to solve?

This paper primarily explores the mechanisms of action of the BH3 domain protein Bid in apoptosis, tumorigenesis, cancer therapy, and aging processes. Specifically:

1. **Dual Role in Apoptosis and Tumorigenesis**:
- The paper focuses on the dual role of Bid protein in regulating apoptosis through the mitochondrial pathway and its role in tumorigenesis and cancer therapy.
- Bid protein and its truncated form tBid are involved in apoptosis in normal cells but may lose function in cancer cells due to binding with anti-apoptotic proteins (such as Bcl-2, Bcl-XL, mitoATR).

2. **Mechanism of Chemoresistance**:
- The study found that in cancer cells, tBid stably binds with anti-apoptotic proteins (such as mitoATR), making these cells resistant to apoptotic signals, leading to chemoresistance.
- This mechanism explains why cancer cells can resist apoptosis even in the presence of a large amount of tBid.

3. **Potential Therapeutic Strategies**:
- A new therapeutic approach is proposed, which involves restoring the apoptotic sensitivity of cancer cells by inhibiting the interaction between tBid and its anti-apoptotic proteins.
- Specific methods include using small molecule inhibitors (such as venetoclax) to competitively bind anti-apoptotic proteins (such as Bcl-2), thereby allowing tBid to activate Bax/Bak and induce apoptosis.

4. **Relationship with Aging and Related Diseases**:
- The role of Bid protein in the aging process is discussed, particularly the phenomenon of apoptosis resistance due to accumulated DNA damage under low-level cellular stress.
- The study suggests that the anti-apoptotic mechanisms in aging cells are similar to those in cancer cells, indicating that targeting these mechanisms may help treat aging-related diseases.

In summary, this review aims to comprehensively evaluate the important roles of Bid protein and its truncated form tBid in apoptosis, tumorigenesis, cancer therapy, and aging, and proposes potential therapeutic strategies to overcome chemoresistance in cancer cells.